Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDR
The experimentally established mechanism targets of Brivanib Alaninate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 5/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 16/20 | 0.75 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.75 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.75 |
| ▸ | FGFR4 known ✓ | P22455 | 1/20 | 0.75 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.75 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 12/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 2/20 | 1.00 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivanib Alaninate SCHEMBL13108648 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL483382 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL2263525 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL28365380 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL29355920 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL29665039 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL15971686 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13412331 | 0.95 | CYP3A4 (0.91) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3450304 | 0.93 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8207945 | 0.91 | CYP3A4 (0.84) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118946359-A | Pharmaceutical combinations of amino-pyrrolopyrimidinone compounds and methods of use | 默沙东有限责任公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114450287-A | SHP2 phosphatase inhibitors and methods of making and using the same | 传达治疗有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3853234-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | Nikang Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3703692-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3661499-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND BENZO[b | Merck Sharp & Dohme Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661498-A1 | BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT | Merck Sharp & Dohme Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2020061103-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3558358-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019027857-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019027858-A1 | BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-3344644-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-3319606-A1 | PHARMACEUTICAL COMPOUND | Iomet Pharma Ltd. (GB) | 2018-05-16 | — | — | EP | disclosed |
| EP-3310774-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2017027645-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017007700-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016203406-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |